R. Zacest

986 total citations
24 papers, 749 citations indexed

About

R. Zacest is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, R. Zacest has authored 24 papers receiving a total of 749 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pharmacology, 6 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in R. Zacest's work include Alkaloids: synthesis and pharmacology (4 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (4 papers). R. Zacest is often cited by papers focused on Alkaloids: synthesis and pharmacology (4 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (4 papers). R. Zacest collaborates with scholars based in Australia, United Kingdom and United States. R. Zacest's co-authors include Jan Koch‐Weser, Edward D. Gilmore, Phillip A. Reece, Edward M. Sellers, M. L. Mashford, Benedetta C. Sallustio, Philip E. Stanley, Benjamin Roberts, Kathleen Knights and P. A. Reece and has published in prestigious journals such as New England Journal of Medicine, Biochemical Pharmacology and Journal of Pharmaceutical Sciences.

In The Last Decade

R. Zacest

24 papers receiving 644 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Zacest Australia	12	224	161	123	114	89	24	749
Ronald Okun United States	16	143 0.6×	143 0.9×	71 0.6×	131 1.1×	42 0.5×	49	802
Peter H. Hinderling United States	19	187 0.8×	252 1.6×	200 1.6×	186 1.6×	100 1.1×	48	1.1k
Ermelinda Sakmar United States	18	67 0.3×	103 0.6×	171 1.4×	148 1.3×	141 1.6×	40	909
A. D. Munro‐Faure United Kingdom	18	278 1.2×	103 0.6×	70 0.6×	50 0.4×	22 0.2×	27	798
H. L. Elliott United Kingdom	14	262 1.2×	119 0.7×	115 0.9×	103 0.9×	124 1.4×	42	683
Aryeh Hurwitz United States	19	85 0.4×	391 2.4×	129 1.0×	112 1.0×	64 0.7×	47	1.2k
M. M. Reidenberg United States	12	80 0.4×	133 0.8×	70 0.6×	70 0.6×	40 0.4×	27	659
Eva Steiness Denmark	20	478 2.1×	300 1.9×	108 0.9×	166 1.5×	86 1.0×	75	1.3k
U. Abshagen Germany	19	247 1.1×	165 1.0×	190 1.5×	139 1.2×	142 1.6×	68	982
P J Meffin Australia	24	371 1.7×	174 1.1×	364 3.0×	274 2.4×	154 1.7×	38	1.2k

Countries citing papers authored by R. Zacest

Since Specialization

Citations

This map shows the geographic impact of R. Zacest's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Zacest with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Zacest more than expected).

Fields of papers citing papers by R. Zacest

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Zacest. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Zacest. The network helps show where R. Zacest may publish in the future.

Co-authorship network of co-authors of R. Zacest

This figure shows the co-authorship network connecting the top 25 collaborators of R. Zacest. A scholar is included among the top collaborators of R. Zacest based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Zacest. R. Zacest is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morris, Raymond G., et al.. (1991). Improved High-Performance Liquid Chromatography Assay for Atenolol in Plasma and Urine Using Fluorescence Detection. Therapeutic Drug Monitoring. 13(4). 345–349. 15 indexed citations

Sallustio, Benedetta C., Kathleen Knights, Benjamin Roberts, & R. Zacest. (1991). In vivo covalent binding of clofibric acid to human plasma proteins and rat liver proteins. Biochemical Pharmacology. 42(7). 1421–1425. 31 indexed citations

Reece, P. A., et al.. (1985). Synthesis, Formulation, and Clinical Pharmacological Evaluation of Hydralazine Pyruvic Acid Hydrazone in two Healthy Volunteers. Journal of Pharmaceutical Sciences. 74(2). 193–196. 8 indexed citations

Reece, P. A., et al.. (1983). Endralazine ? A new hydralazine-like antihypertensive with high systemic bioavailability. European Journal of Clinical Pharmacology. 25(4). 553–556. 1 indexed citations

Zacest, R. & P. A. Reece. (1982). Intravenous administration of hydrallazine. The Medical Journal of Australia. 1(12). 497–498. 2 indexed citations

Reece, P. A., et al.. (1982). Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine. European Journal of Clinical Pharmacology. 23(6). 523–527. 8 indexed citations

Zacest, R., et al.. (1981). Relationship of Psychological Factors to Failure of Antihypertensive Drug Treatment. Australian and New Zealand Journal of Medicine. 11(4). 501–507. 1 indexed citations

Reece, Phillip A., et al.. (1981). Sensitive high-performance liquid chromatographic assay for endralazine and two of its metabolites in human plasma. Journal of Chromatography B Biomedical Sciences and Applications. 225(1). 151–160. 9 indexed citations

Reece, Phillip A., et al.. (1980). Kinetics of hydralazine and its main metabolites in slow and fast acetylators. Clinical Pharmacology & Therapeutics. 28(6). 769–778. 45 indexed citations

10.

Reece, Phillip A., et al.. (1980). Selective high-performance liquid chromatographic assays for hydralazine and its metabolites in plasma of man. Journal of Chromatography B Biomedical Sciences and Applications. 181(3-4). 427–440. 27 indexed citations

11.

Reece, Phillip A., Philip E. Stanley, & R. Zacest. (1978). Interference in Assays for Hydralazine in Humans by a Major Plasma Metabolite, Hydralazine Pyruvic Acid Hydrazone. Journal of Pharmaceutical Sciences. 67(8). 1150–1153. 33 indexed citations

12.

Koch‐Weser, Jan, Edward M. Sellers, & R. Zacest. (1977). The ambiguity of adverse drug reactions. European Journal of Clinical Pharmacology. 11(2). 75–78. 98 indexed citations

13.

Zacest, R.. (1976). The Vasodilator—Beta‐Blocker Interaction—Some Determinants of its Clinical Success. Australian and New Zealand Journal of Medicine. 6(S3). 65–76. 3 indexed citations

14.

Zacest, R., et al.. (1976). Clinical and Haemodynamic Effects of Minoxidil in Refractory Hypertension. Drugs. 11(Supplement 1). 177–184. 11 indexed citations

15.

Zacest, R., et al.. (1974). STUDIES OF PLASMA BRADYKININASES USING RADIOLABELED SUBSTRATES. Immunology and Cell Biology. 52(4). 601–606. 16 indexed citations

16.

Zacest, R. & Jan Koch‐Weser. (1972). Relation of Propranolol Plasma Level to <i>β</i>-Blockade during Oral Therapy. Pharmacology. 7(3). 178–184. 51 indexed citations

17.

Colman, RW, et al.. (1971). The human plasma kallikrein-kinin system.. PubMed. 7(0). 255–98. 15 indexed citations

18.

Mashford, M. L. & R. Zacest. (1967). EFFECT OF ADRENALINE ON BLOOD KININ LEVELS IN CARCINOID SYNDROME AND IN NORMAL SUBJECTS. Australasian Annals of Medicine. 16(4). 326–329. 3 indexed citations

19.

Mashford, M. L. & R. Zacest. (1967). PHYSIOLOGICAL CHANGES IN BLOOD BRADYKININ LEVELS IN MAN. Immunology and Cell Biology. 45(6). 661–673. 9 indexed citations

20.

Zacest, R. & M. L. Mashford. (1967). BLOOD BRADYKININ LEVELS IN THE HUMAN. Immunology and Cell Biology. 45(1). 89–95. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact